Mergers & Acquisitions ·
Supernus Pharmaceuticals reported second quarter 2026 total revenues of $219.1 million, a 32% increase year-over-year…
SUPNSupernus, Inc.
Supernus Pharmaceuticals reported second quarter 2026 total revenues of $219.1 million, a 32% increase year-over-year, driven by strong growth in its four key products: Qelbree ($89.2 million), GOCOVRI ($37.6 million), ONAPGO ($13.5 million), and ZURZUVAE collaboration revenue ($35.4 million). The company raised its full year 2026 financial guidance, projecting total revenues between $860 million and $890 million and adjusted operating earnings of $150 million to $180 million. Supernus also announced a definitive agreement to merge with Indivior Pharmaceuticals in an all-stock merger of equals, creating a diversified central nervous system biopharmaceutical company. The combined entity aims to leverage scale and growth opportunities across the CNS therapeutic space.